SEC 13F Intelligence

Zebra Capital Management LLC / HALO

Zebra Capital Management LLC’s Halozyme Therapeutics Inc Position

Does Zebra Capital Management LLC own Halozyme Therapeutics Inc (HALO)? Yes — 6.7K shares worth $256,000 (+1.28% of its 13F portfolio) as of Q1 2023, up from 6.0K shares the prior filed quarter.

Position Value
$256,000
Q1 2023
Shares
6.7K
% of Portfolio
+1.28%
Quarters Held
10
currently held

Position History HALO

Reported value by quarter
Q3 ’19: $211,000Q3 ’19Q1 ’21: $432,000Q2 ’21: $425,000Q2 ’21Q3 ’21: $376,000Q4 ’21: $272,000Q4 ’21Q1 ’22: $250,000Q2 ’22: $303,000Q2 ’22Q3 ’22: $208,000Q4 ’22: $344,000Q4 ’22Q1 ’23: $256,000filingsflow.com
QuarterSharesValue% of Portfolio
Q1 20236.7K$256,000+1.28%
Q4 20226.0K$344,000+1.20%
Q3 20225.3K$208,000+0.79%
Q2 20226.9K$303,000+0.89%
Q1 20226.3K$250,000+0.57%
Q4 20216.8K$272,000+0.44%
Q3 20219.3K$376,000+0.46%
Q2 20219.3K$425,000+0.50%
Q1 202110.4K$432,000+0.48%
Q3 201913.5K$211,000+0.23%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Zebra Capital Management LLC’s full portfolio or all institutional holders of HALO.